MedTrace Logo

Sero-prevalence of Coronavirus Disease 2019 (COVID-19) in Healthcare Workers

NCT04424017 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1546

Last updated 2021-03-09

No results posted yet for this study

Summary

The medical and paramedical staff of the front-line services are potentially exposed to SARS-CoV-2. Therefore, despite the application of standard protective measures, it is possible that a certain number of these personnel have already contracted SARS-CoV-2, including in its asymptomatic form. Serological testing in this context would be useful for deploying immune healthcare workers as to limit the risk of viral infection and transmission. Therefore, it is of utmost importance to prove that the serological response entails the production of neutralizing antibodies.

Conditions

  • COVID
  • Corona Virus Infection

Interventions

BIOLOGICAL

Specific anti-SARS-CoV-2 antibodies

A serum sample needs to be collected from each participant upon recruitment into the investigation All samples will be tested by the rapid test (Artron, Artron Laboratories, Burnaby, Canada), IgM / IgG which is an antibody capture Immunochromatografac assay for simultaneous detection of IgM and IgG in serum or plasma for COVID -19 in samples. All samples will be tested for total Immunoglobulins and IgG in samples for COVID-19 virus by Ortho clinical diagnostics chemiluminescent technique (Ortho, Raritan, USA).

Sponsors & Collaborators

  • Cairo University

    collaborator OTHER

  • National Research Centre, Egypt

    collaborator OTHER

  • Academy of Scientific Research and Technology, Egypt

    collaborator OTHER

  • Egyptian Center for Research and Regenerative Medicine

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-07
Primary Completion
2020-10-30
Completion
2020-10-30

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04424017 on ClinicalTrials.gov